WEgovy Real World Assessment of Weight Loss in Korea

December 10, 2025 updated by: Novo Nordisk A/S

WEgovy Real World Assessment of Weight Loss in Korea (WE-WALK): a Multi-centre, Prospective, Single-arm, Nonintervention Study to Investigate the Effectiveness and Safety of Once-weekly Semaglutide 2.4 mg for People Living With Obesity in Routine Clinical Practice in Korea

This study is to investigate the effectiveness and safety of Wegovy (semaglutide) in Korean patients living with obesity in routine clinical practice. The purpose of this study is to investigate the change in body weight and other clinical characteristics related to body weight in patients living with obesity. Participants will be treated with Wegovy (semaglutide) as prescribed by their doctor, in accordance with normal clinical practice. The study will last for about 52 weeks.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Enrolling by invitation

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • South Korea
      • Daejeon, South Korea, 35220
        • Daejeon Endo Internal Medicine Clinic

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Participants will be treated with commercially available semaglutide. The treating physician will initiate treatment with commercially available semaglutide prior to and independently from the decision to include the participant in the study.

Description

Inclusion Criteria:

  1. Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
  2. The decision to initiate treatment with commercially available Wegovy (semaglutide) has been made by the patient and the treating physician before and independently from the decision to include the patient in this study.
  3. Initiating treatment with Wegovy (semaglutide) for the first time and according to locally approved label.
  4. Male or female, aged ≥ 19 years at the time of signing the informed consent.

Exclusion Criteria:

  1. Previous participation in clinical studies including treatment with Wegovy (semaglutide). Participation is defined as providing informed consent in a previous study.
  2. Female patient who is pregnant, breast-feeding, or intends to become pregnant and is of childbearing potential not using adequate contraceptive methods (adequate contraceptive measures as required by local regulation or practice).
  3. Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Once weekly Wegovy
Participants will be treated with commercially available semaglutide. The treating physician will initiate treatment with commercially available semaglutide prior to and independently from the decision to include the participant in the study.
Drug: Semaglutide
Semaglutide injection will be self-administered once weekly subcutaneously.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Percentage change in body weight
Time Frame: From baseline (week 0) to 24 weeks
Percent (%)
From baseline (week 0) to 24 weeks

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Absolute change in body weight
Time Frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Kilogram (kg)
From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Percentage change in body weight
Time Frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Percent (%)
From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Achievement in body weight reduction more than or equal to (≥) 5%
Time Frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Count of patients
From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Achievement in body weight reduction ≥ 10%
Time Frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Count of patients
From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Achievement in body weight reduction ≥ 15%
Time Frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Count of patients
From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Achievement in body weight reduction ≥ 20%
Time Frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Count of patients
From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in body composition of Lean body mass
Time Frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Kg
From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in body composition of Total fat mass
Time Frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Kg
From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in body composition of Lean body mass
Time Frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Percent (%)
From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in body composition of Total fat mass
Time Frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Percent (%)
From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in Body mass index (BMI)
Time Frame: From baseline (week 0) up to 8, 16, 24, 32, 40, 52 weeks
Kilogram per meter square (kg/m^2)
From baseline (week 0) up to 8, 16, 24, 32, 40, 52 weeks
Change in the proportion of patients by BMI Class I obesity (25 to 29.9 kg/m^2)
Time Frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Count of patients
From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in the proportion of patients by BMI Class II obesity (30 to 34.9 kg/m^2)
Time Frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Count of patients
From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in the proportion of patients by BMI Class III obesity (≥35 kg/m^2)
Time Frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Count of patients
From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in waist circumference
Time Frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Centimetre (cm)
From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Systolic blood pressure (SBP)
Time Frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Millimetres of mercury (mmHg)
From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Diastolic blood pressure (DBP)
Time Frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
mmHg
From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Fasting plasma glucose (FPG)
Time Frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Milligram per deciliter (mg/dL)
From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Haemoglobin A1c (HbA1c)
Time Frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Percent (%)
From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Lipids: total cholesterol (TCh)
Time Frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
mg/dL
From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Lipids: high-density lipoprotein cholesterol (HDL-C)
Time Frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
mg/dL
From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Lipids: low-density lipoprotein cholesterol (LDL-C)
Time Frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
mg/dL
From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Lipids: triglycerides (TG)
Time Frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
mg/dL
From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Lipids: free fatty acid (FFA)
Time Frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
mg/dL
From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in status of type two diabetes mellitus (T2DM)
Time Frame: Baseline (week 0) to 52 weeks [or end of the study (EOS)]
Count of patients
Baseline (week 0) to 52 weeks [or end of the study (EOS)]
Change in status of Hypertension
Time Frame: Baseline (week 0) to 52 weeks (or EOS)
Count of patients
Baseline (week 0) to 52 weeks (or EOS)
Change in status of Dyslipidemia
Time Frame: Baseline (week 0) to 52 weeks (or EOS)
Count of patients
Baseline (week 0) to 52 weeks (or EOS)
Number of treatment-emergent adverse events (TEAEs)
Time Frame: From baseline (week 0) to 52 weeks (or EOS)
Count of events
From baseline (week 0) to 52 weeks (or EOS)
Number of serious TEAEs
Time Frame: From baseline (week 0) to 52 weeks (or EOS)
Count of events
From baseline (week 0) to 52 weeks (or EOS)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Novo Nordisk A/S

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Clinical Transparency dept. 2834, Novo Nordisk A/S

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
November 10, 2025

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
October 31, 2027

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
October 31, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 24, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 10, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
December 12, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
December 12, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 10, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
December 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • NN9536-7850
  • U1111-1306-1595 (Other Identifier: WHO)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on Semaglutide

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings